<DOC>
	<DOC>NCT02963831</DOC>
	<brief_summary>This is a two-part Phase 1/2 dose escalation and dose expansion study of the GMCSFencoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.</brief_summary>
	<brief_title>A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Subjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of platinumresistant or refractory epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, cervical cancer, vaginal and vulvar cancer, uterine sarcomas including leiomyosarcoma, carcinosarcoma or high grade endometrial stromal sarcoma, gastroesophageal cancer, pancreatic cancer, cholangiocarcinoma, colorectal cancer, gastrointestinal neuroendocrine tumors, or mesothelioma will be enrolled. 2. The subject is willing to undergo a core needle biopsy during screening and during Cycle 2, Study Week 5. Archival tumor samples are requested, but are not required for eligibility. 3. Previously treated for advanced cancer with no additional therapy options available known to prolong survival. 4. Laboratory parameters for vital functions should be in the normal range or not clinically significant. 5. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 1 1. Treatment with an investigational agent within 4 weeks of starting study treatment or prior treatment with a checkpoint inhibitor (cytotoxic Tlymphocyteassociated protein 4 (CTLA4), programmed cell death protein 1 (PD1) or programmed death ligand 1 (PDL1) antibodies). 2. Subjects with known active central nervous system metastasis, glioma and nervous system malignancies including carcinomatous meningitis or other invasive malignancy within 5 years except for noninvasive malignancies such as cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured. 3. Known immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled intercurrent illnesses. 4. Ongoing bowel perforation or presence of bowel fistula or abscess or history of small or large bowel obstruction within 3 months of registration, including subjects with palliative gastric drainage catheters. Subjects with palliative diverting ileostomy or colostomy are allowed if they have been symptomfree for more than 3 months. 5. Subjects with clinically significant cardiovascular disease, history of organ transplant or allogeneic bone marrow transplant, active known or history of autoimmune disease that might recur or major surgery within 28 days prior to the first dose or still recovering from prior surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oncos-102</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Peritoneal</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>